Treatment Outcomes of Esophageal Cancer
ConditionEsophageal Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco
About this trial
This study will be a carried out through a prospective observational cohort design in conjunction with researchers in the African Esophageal Cancer Consortium (AfrECC). The purpose of this research is to prospectively evaluate outcomes related to existing treatment strategies for esophageal cancer (EC) at participating sites within AfrECC.
Eligibility criteria
Qualifiers
Participants with histopathologically confirmed or presumptive clinical diagnosis of EC. For patients who do not have histopathologically confirmed disease, presumptive clinical diagnosis may be based upon barium swallow or endoscopy without biopsy.
Age 18 years of age or older;
Disqualifiers
Unable to provide informed consent
Trial design
Treatments tested in this trial
- Assessment of patient-reported outcomes (PROs)
Treatment groups
2,476 Participants
are divided into 1 treatment groupSponsors and collaborators
University of California, San Francisco
Lead sponsor
Westat
Collaborator
African Esophageal Cancer Consortium (AfrECC)
Collaborator
Celgene Corporation
Collaborator
Source ClinicalTrials.gov